FDA sets Feb decision date for Libtayo lung cancer challenge to KeytrudaThe FDA has started a priority review of Regeneron and Sanofi’s checkpoint inhibitor Libtayo in first-line non-small cell Share XFDA sets Feb decision date for Libtayo lung cancer challenge to Keytrudahttps://pharmaphorum.com/news/fda-sets-feb-decision-date-for-libtayos-lung-cancer-challenge-to-keytruda/
Takeda to partner on patient-centric data with SeqsterTakeda has partnered with patient data firm Seqster in a drive to improve care through better access and Share XTakeda to partner on patient-centric data with Seqsterhttps://pharmaphorum.com/news/takeda-to-partner-on-patient-centric-data-with-seqster/
Novartis keeps a close eye on gene therapy with Vedere Bio buyAlready a major player in gene therapy, Novartis has swooped on US startup Vedere Bio in a $280 Share XNovartis keeps a close eye on gene therapy with Vedere Bio buyhttps://pharmaphorum.com/news/novartis-keeps-a-close-eye-on-gene-therapy-with-vedere-bio-buy/
Gilead Q3 revenue rise bolstered by $873m Veklury salesGilead Sciences is the first and so far only company to claim FDA approval for a COVID-19 treatment Share XGilead Q3 revenue rise bolstered by $873m Veklury saleshttps://pharmaphorum.com/news/gilead-q3-revenue-rise-bolstered-by-873m-veklury-sales/
BMS joins forces with insitro to develop neurodegenerative treatmentsinsitro has landed another big biopharma partnership, signing a five-year collaboration with Bristol Myers Sqibb to develop therapies Share XBMS joins forces with insitro to develop neurodegenerative treatmentshttps://pharmaphorum.com/news/bms-joins-forces-with-insitro-to-develop-neurodegenerative-treatments/
Vaccine sales recover at GSK in Q3, but lockdown fears weigh on sharesGlaxoSmithKline saw a recovery in its vaccine sales in the third quarter after a big hit in the Share XVaccine sales recover at GSK in Q3, but lockdown fears weigh on shareshttps://pharmaphorum.com/news/vaccine-sales-recover-at-gsk-in-q3-but-lockdown-fears-weigh-on-shares/
US buys Lilly COVID antibody, as effectiveness questions remainThe US government said it will buy 300,000 doses of Eli Lilly’s COVID-19 therapy bamlanivimab for $375 million Share XUS buys Lilly COVID antibody, as effectiveness questions remainhttps://pharmaphorum.com/news/us-buys-300000-doses-lilly-covid-antibody/
Exact Sciences buys cancer detection company Thrive for $2.15 billionStocks for Exact Sciences leaped 33% after it announced the acquisition of liquid biopsy rival Thrive and UK Share XExact Sciences buys cancer detection company Thrive for $2.15 billionhttps://pharmaphorum.com/news/exact-sciences-buys-early-cancer-detection-company-thrive-for-2-15-billion/
FDA sets April verdict for Pfizer’s “underestimated” atopic dermatitis drugPfizer could be just a few months away from getting FDA approval for its JAK1 inhibitor abrocitinib in Share XFDA sets April verdict for Pfizer’s “underestimated” atopic dermatitis drughttps://pharmaphorum.com/news/fda-sets-april-verdict-for-pfizers-underestimated-atopic-dermatitis-drug/
